Suramab, a novel antiangiogenic agent, reduces tumor growth and corneal neovascularization

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 3, 2011, Pages 723-728

  Lopez, Emiliano S ^a   Rizzo, Manglio M ^a   Croxatto, J Oscar ^b   Mazzolini, Guillermo ^a   Gallo, Juan E ^a  

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b Fundacion Oftalmologica Argentina Jorge Malbran   (Argentina)

Author keywords

Angiogenesis; Bevacizumab; Cancer; Cornea; Suramin

Indexed keywords

BEVACIZUMAB; SURAMIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; EXPERIMENTAL RABBIT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; COLORECTAL TUMOR; COMPARATIVE STUDY; DISEASE MODEL; DRUG COMBINATION; INJECTION; PATHOLOGY; RABBIT; SURVIVAL; TIME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG SYNERGISM; INJECTIONS; MALE; MICE; MICE, INBRED BALB C; RABBITS; SURAMIN; SURVIVAL; TIME FACTORS;

EID: 79953785200     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1457-z     Document Type: Article

References (20)

1. N Ferrara RS Kerbel 2005 Angiogenesis as a therapeutic target Nature 438 7070 10.1038/nature04483 (Pubitemid 43093963)
2. Williams KA, Lowe M, Bartlett C, Kelly TL, Coster DJ (2008) Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation 86(12):1720-1724
3. R Manzano GA Peyman P Khan PE Carvounis M Kivilcim M Ren JC Lake P Chévez-Barrios 2007 Inhibition of experimental corneal neovascularisation by Bevacizumab (Avastin) Br J Ophthalmol 91 804 807 10.1136/bjo.2006.107912 17179168 (Pubitemid 46846656)
4. M Erdurmus Y Totan 2007 Subconjunctival bevacizumab for corneal neovascularization Graefe's Arch Clin Exp Ophthalmol 245 1577 1579 1:CAS:528:DC%2BD2sXhtVajs73M 10.1007/s00417-007-0587-4 (Pubitemid 47423342)
5. R Greil M Moik R Reitsamer S Ressler M Stoll K Namberger C Menzel B Mlineritsch 2009 Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: efficacy and safety in a phase II pilot study Eur J Surg Oncol 35 1048 1054 1:STN:280: DC%2BD1Mnhs1KnsQ%3D%3D 19250795
6. AA Moshfeghi PJ Rosenfeld CA Puliafito S Michels EN Marcus JD Lenchus AS Venkatraman 2006 Systemic Bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study Ophthalmology 113 2002 2011 10.1016/j.ophtha.2006.05. 070 17027972 (Pubitemid 44642322)
7. N Jo C Mailhos M Ju E Cheung J Bradley K Nishijima GS Robinson AP Adamis DT Shima 2006 Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization Am J Pathol 168 2036 2053 1:CAS:528:DC%2BD28XlvVOhsbg%3D 10.2353/ajpath.2006.050588 16723717 (Pubitemid 43825322)
8. S Sarman J Mancini I van der Ploeg JO Croxatto A Kvanta JE Gallo 2008 Involvement of purinergic p2 receptors in experimental retinal neovascularization Curr Eye Res 33 285 291 1:CAS:528:DC%2BD1cXjtlygsbw%3D 10.1080/02713680701885470 18350440
9. MP Abbracchio G Burnstock 1994 Purinuceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther 64 445 475 1:CAS:528:DyaK2MXjtVOrtrc%3D 10.1016/0163-7258(94)00048-4 7724657 (Pubitemid 24381231)
10. G Bocci R Danesi U Benelli F Innocenti A Di Paolo S Fogli M Del Tacca 1999 Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo Cancer Chemother Pharmacol 43 205 212 1:CAS:528:DyaK1MXhvFWrsLw%3D 10.1007/s002800050885 9923550 (Pubitemid 29042488)
11. CA Stein 1993 Suramin: a novel antineoplastic agent with multiple potential mechanisms of action Cancer Res 53 Suppl 2239 2248 1:CAS:528:DyaK3sXks1ahtrs%3D 8485709 (Pubitemid 23156807)
12. J Waltenberger U Mayr H Frank V Hombach 1996 Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action J Mol Cell Cardiol 28 1523 1529 1:CAS:528:DyaK28Xks1WmsLY%3D 10.1006/jmcc.1996.0142 8841939 (Pubitemid 26340906)
13. HS Lee SK Chung 2010 The effect of subconjunctival suramin on corneal neovascularization in rabbits Cornea 29 1 86 92 10.1097/ICO.0b013e3181ae91e3 19907290
14. Lopez ES Croxatto JO, Kvanta A, and Gallo JE(2007). Effect of Bevacizumab (Avastin) and Suramin in a rabbit model of corneal neovascularization. Invest Ophthalmol Vis Sci 48: E-Abstract 1717
15. LD Ormerod MB Abelson KR Kenyon 1989 Standard models of corneal injury using Alcali-Inmersed filter discs Invest Ophthalmol Vis Sci 30 2148 2153 1:STN:280:DyaK3c%2Fgsl2qsA%3D%3D 2477342 (Pubitemid 19259917)
16. JH Chang EE Gabison T Kato DT Azar 2001 Corneal neovascularization Curr Opin Ophthalmol 12 242 249 1:STN:280:DC%2BD3Mvmt1aitg%3D%3D 10.1097/00055735- 200108000-00002 11507336 (Pubitemid 32751680)
17. Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S (2010) Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye (Lond) 24(5):816-824
18. Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, Zhang Y, Eng C, Grever M, Au JL(2008) Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study 19:1903-1909
19. F Luengo Gimeno V Lavigne S Gatto JO Croxatto L Correa JE Gallo 2007 Advances in corneal stem-cell transplantation in rabbits with severe ocular alkali burns J Cataract Refract Surg 33 1958 1965 10.1016/j.jcrs.2007.07.020 17964405 (Pubitemid 47628811)
20. G Strassman M Fong CE Freter S Windsor F D'Alessandro RP Nordan 1993 Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo J Clin Invest 92 2152 2159 10.1172/JCI116816 (Pubitemid 23333518)